Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine

The aim of this study was to assess the cost-effectiveness, from a health care perspective, of adding rituximab to fludarabine and cyclophosphamide scheme (FCR versus FC) for treatment-naïve and refractory/relapsed Ukrainian patients with chronic lymphocytic leukemia. A decision-analytic Markov coho...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandrik, Olena, Corro Ramos, Isaac, Knies, Saskia, Al, Maiwenn, Severens, Johan L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555968/
https://www.ncbi.nlm.nih.gov/pubmed/26345331
http://dx.doi.org/10.2147/CMAR.S79258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555968/
https://www.ncbi.nlm.nih.gov/pubmed/26345331
http://dx.doi.org/10.2147/CMAR.S79258

Ejemplares similares